REGN (Regeneron Pharmaceuticals, Inc.) Stock Financials & Earnings

REGNRegeneron Pharmaceuticals, Inc.

Mkt Cap$81B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$14.3B

Net Income (TTM)$4.5B

EPS (TTM)$41.56

Free Cash Flow (TTM)$4.1B

Gross Margin85.4%

Op. Margin24.9%

Net Margin31.4%

FCF Margin28.4%

P/S Ratio (TTM)5.7x

P/E Ratio (TTM)18.0x

YoY Rev Growth+1.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$3.2B	$2.6B	$1.0B
Q2 23	$3.2B	$2.7B	$1.0B
Q3 23	$3.4B	$2.8B	$1.2B
Q4 23	$3.4B	$2.8B	$1.1B
Q1 24	$3.1B	$2.7B	$751M
Q2 24	$3.5B	$3.1B	$1.1B
Q3 24	$3.7B	$3.2B	$1.2B
Q4 24	$3.8B	$3.2B	$990M
Q1 25	$3.0B	$2.6B	$592M
Q2 25	$3.7B	$3.1B	$1.1B
Q3 25	$3.8B	$3.2B	$1.0B
Q4 25	$3.9B	$3.3B	$880M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Collaboration Revenue	Product	Product and Service, Other
Q1 23	$1.4B	$1.7B	$116M
Q2 23	$1.3B	$1.8B	$69M
Q3 23	$1.4B	$1.8B	$138M
Q4 23	$1.4B	$1.9B	$213M
Q1 24	$1.3B	$1.8B	$117M
Q2 24	$1.5B	$1.9B	$105M
Q3 24	$1.7B	$1.9B	$114M
Q4 24	$1.6B	$2.0B	$179M
Q1 25	$1.5B	$1.4B	$82M
Q2 25	$1.9B	$1.6B	$184M
Q3 25	$2.0B	$1.6B	$198M
Q4 25	$2.0B	$1.7B	$239M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$3.9B	$5.0B	$9.0B
Q2 23	$1.9B	$7.0B	$8.9B
Q3 23	$2.2B	$7.8B	$9.9B
Q4 23	$2.7B	$8.1B	$10.8B
Q1 24	$2.6B	$7.9B	$10.5B
Q2 24	$1.9B	$7.9B	$9.8B
Q3 24	$2.0B	$7.8B	$9.8B
Q4 24	$2.5B	$6.5B	$9.0B
Q1 25	$3.1B	$5.3B	$8.3B
Q2 25	$2.0B	$5.5B	$7.5B
Q3 25	$2.5B	$5.9B	$8.4B
Q4 25	$3.1B	$5.5B	$8.6B

Shares Outstanding

Revenue Per Employee

Revenue / Employee